Please use a PC Browser to access Register-Tadawul
Get It
Forecasting The Future: 4 Analyst Projections For Zymeworks
Zymeworks Inc. +3.23% Pre
Zymeworks Inc. ZYME | 23.62 23.62 | +3.23% 0.00% Pre |
Analysts' ratings for Zymeworks (NASDAQ:ZYME) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 2 | 0 | 0 | 0 |
| Last 30D | 1 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 1 | 1 | 0 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $44.5, a high estimate of $58.00, and a low estimate of $33.00. Observing a 14.1% increase, the current average has risen from the previous average price target of $39.00.
Diving into Analyst Ratings: An In-Depth Exploration
The analysis of recent analyst actions sheds light on the perception of Zymeworks by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Stephen Willey | Stifel | Raises | Buy | $47.00 | $40.00 |
| Andrew Berens | Leerink Partners | Raises | Outperform | $58.00 | $52.00 |
| Asthika Goonewardene | Truist Securities | Announces | Buy | $40.00 | - |
| Eva Fortea Verdejo | Wells Fargo | Raises | Overweight | $33.00 | $25.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Zymeworks. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Zymeworks compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Zymeworks's stock. This comparison reveals trends in analysts' expectations over time.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Zymeworks's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Zymeworks analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Get to Know Zymeworks Better
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Zymeworks's Financial Performance
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Zymeworks's remarkable performance in 3M is evident. As of 30 September, 2025, the company achieved an impressive revenue growth rate of 72.59%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Zymeworks's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -70.99%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Zymeworks's ROE stands out, surpassing industry averages. With an impressive ROE of -5.99%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -4.87%, the company showcases effective utilization of assets.
Debt Management: Zymeworks's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.06.
Analyst Ratings: What Are They?
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
